Ab­b­Vie grap­ples with an­oth­er set­back as 2 PhI­II tri­als for its PARP veli­parib flop

Up un­til now, PARP in­hibitors have been blaz­ing a broad, long trail of suc­cess in the clin­ic, with Lyn­parza, Rubra­ca and now Ze­ju­la hit­ting a busy and grow­ing mar­ket for can­cer pa­tients.

But Ab­b­Vie $AB­BV won’t be join­ing that crowd any­time soon.

Re­searchers at the com­pa­ny chose to an­nounce late Wednes­day that their PARP, veli­parib, failed in two Phase III stud­ies in pa­tients with squa­mous non-small cell lung can­cer (NSCLC) and triple neg­a­tive breast can­cer.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER